Nxera Pharma Co., Ltd. SOLTF
Set alert
At close · Oct 30
- YTD
- +55.11%
- 1 year
- +38.44%
- Open
- 8.50
- Prev close
- 8.50
- Mkt cap
- 776.69M
- Vol
- 100
- Avg vol
- 85
- EPS
- -0.40
- P/E
- 0.00
More statistics
- Low
- 8.50
- High
- 8.50
News
1 day ago seekingalpha.com
Nxera Pharma Co., Ltd. (SOLTF) Q3 2026 Earnings Call Transcript
Nxera Pharma Co., Ltd. (SOLTF) Q3 2026 Earnings Call Transcript
2 months ago seekingalpha.com
Nxera Pharma Co., Ltd. (SOLTF) Q2 2026 Earnings Call Transcript
Nxera Pharma Co., Ltd. (SOLTF) Q2 2026 Earnings Call Transcript
4 months ago globenewswire.com
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the…
5 months ago globenewswire.com
Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
Tokyo, Japan and Cambridge, UK, 2 June 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan…
5 months ago globenewswire.com
Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026
Tokyo, Japan and Cambridge, UK, 26 May 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat' at the…
5 months ago globenewswire.com
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) entered into a license agreement with a newly established company…
5 months ago globenewswire.com
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”)…
6 months ago globenewswire.com
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Tokyo, Japan and Cambridge and London, UK, 20 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a third R&D milestone under its multi-target…
6 months ago defenseworld.net
Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF) Short Interest Update
Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF - Get Free Report) saw a significant decline in short interest in March. As of March 31st, there was short interest totaling 1,523,938 shares, a decline of 13.8%…
6 months ago globenewswire.com
Nxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Tokyo, Japan and Cambridge, UK, 14 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Holling Bio-Pharma Corp. (“Holling”), a leading pharmaceutical…
6 months ago globenewswire.com
Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
Tokyo, Japan and Cambridge, UK, 13 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated…
6 months ago globenewswire.com
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Tokyo, Japan and Cambridge, UK, 09 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target…
7 months ago globenewswire.com
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa's OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and…
8 months ago globenewswire.com
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development…
8 months ago globenewswire.com
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Tokyo, Japan and Cambridge, UK, 4 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the Ministry…
8 months ago seekingalpha.com
Nxera Pharma Co., Ltd. (SOLTF) Q4 2025 Earnings Call Transcript
Nxera Pharma Co., Ltd. (SOLTF) Q4 2025 Earnings Call Transcript
8 months ago globenewswire.com
Nxera Pharma Proposes Changes to its Board of Directors
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated…
8 months ago globenewswire.com
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for…
8 months ago globenewswire.com
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone…
8 months ago globenewswire.com
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has entered into a license agreement (the “Agreement”) with a newly…